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A B S T R A C T
Introduction: Antenatal depression is associated with a broad range of suboptimal outcomes in oﬀspring, al-
though the underlying mechanisms are not yet understood. Animal studies propose inﬂammation and gluco-
corticoids as mediators of the developmental programming eﬀect of prenatal stress on oﬀspring stress responses,
but studies in humans are not yet at this stage. Indeed, to date no single study has examined the eﬀects of a
rigorously deﬁned, clinically signiﬁcant Major Depressive Disorder (MDD) in pregnancy on maternal antenatal
inﬂammatory biomarkers and hypothalamic-pituitary (HPA) axis, as well as on oﬀspring HPA axis, behavior and
developmental outcomes in the ﬁrst postnatal year.
Methods: A prospective longitudinal design was used in 106 women (49 cases vs. 57 healthy controls) to study
the eﬀect of MDD in pregnancy and associated antenatal biology (inﬂammatory and cortisol biomarkers), on
oﬀspring stress response (cortisol response to immunization, at 8 weeks and 12 months), early neurobehavior
(Neonatal Behavioral Assessment Scale, NBAS, at day 6), and cognitive, language and motor development
(Bayley Scales of Infant and Toddler Development at 12 months).
Results: Compared with healthy controls, women with MDD in pregnancy had raised interleukin (IL) IL-6 (eﬀect
size (δ)= 0.53, p= 0.031), IL-10 (δ=0.53, p=0.043), tumor necrosis factor alpha (δ=0.90, p=0.003) and
vascular endothelial growth factor (δ=0.56, p=0.008), together with raised diurnal cortisol secretion
(δ=0.89, p= 0.006), raised evening cortisol (δ=0.64, p=0.004), and blunted cortisol awakening response
(δ=0.70, p= 0.020), and an 8-day shorter length of gestation (δ=0.70, p= 0.005). Furthermore, they had
neonates with suboptimal neurobehavioral function in four out of ﬁve NBAS clusters measured (range of
δ=0.45–1.22 and p= 0.049–<0.001) and increased cortisol response to stress at one year of age (δ=0.87,
p < 0.001). Lastly, maternal inﬂammatory biomarkers and cortisol levels were correlated with infant stress
response, suggesting a mechanistic link.
Conclusion: This study conﬁrms and extends the notion that depression in pregnancy is associated with altered
oﬀspring behavior and biological stress response, and demonstrates that changes in maternal antenatal stress-
related biology are associated with these infant outcomes.
1. Introduction
In clinical studies, depression in pregnancy (antenatal depression)
has been recognized as a key clinical risk factor for the transmission of
abnormal mental health and behavior to the oﬀspring generation, over
and above the eﬀects of disrupted maternal care due to postnatal
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depression (Davis et al., 2007; Pawlby et al., 2009; Gerardin et al.,
2010; Hay et al., 2010; Pearson et al., 2013; Van Batenburg-Eddes et al.,
2013). These eﬀects of antenatal depression are wide-ranging, and in-
clude adverse eﬀects on neonatal behavior (Zuckerman et al., 1990;
Field et al., 2004a; Diego et al., 2005; Goodman et al., 2011; Pacheco
and Figueiredo, 2012), infant development (Deave et al., 2008; Previti
et al., 2014) and mental health later in childhood and adolescence
(Davis et al., 2007; Pawlby et al., 2009; Hay et al., 2010; Pawlby et al.,
2011; Pearson et al., 2013; Plant et al., 2013; Van Batenburg-Eddes
et al., 2013; Previti et al., 2014; Stein et al., 2014; Plant et al., 2015,
2016; Plant et al., 2017). These speciﬁc antenatal eﬀects point toward a
direct biological eﬀect of the in utero environment during depression
on fetal brain development, resulting in the programming of an ab-
normal behavioral and biological stress response, eventually translating
to increased psychopathology later in life; but this model is largely
based on animal studies and limited human evidence (Glover, 2015). In
humans, we still do not know the exact molecular and clinical me-
chanisms underlying the association between adverse in utero en-
vironment and oﬀspring behavioral development.
Although mechanisms for developmental programming in humans
are likely to be complex, it is postulated that, as in animals, exposure of
the fetus to high levels of inﬂammatory biomarkers or glucocorticoids is
a key mediator, resulting in subsequent eﬀects on HPA axis, behavior,
and cognitive function of the oﬀspring (Seckl, 2001, 2004; Seckl and
Holmes, 2007; Cottrell and Seckl, 2009; Reynolds, 2013; Bolton and
Bilbo, 2014; Moisiadis and Matthews, 2014a, b; Debnath et al., 2015;
Glover, 2015; Segovia et al., 2017). While current research lends sup-
port to this hypothesis, to date studies have largely used symptoms of
depression in the general population as a paradigm for prenatal stress,
rather than clinically signiﬁcant, operationally deﬁned, antenatal major
depressive disorder (MDD). The advantage of examining MDD is that
symptoms are at a disease level, thereby ensuring that stress is mean-
ingful and produces clinically signiﬁcant impairment. Indeed, studies of
symptoms of depression in pregnancy have provided some evidence of
the same altered inﬂammation and HPA axis activity found in depres-
sion outside of pregnancy (Pariante and Lightman, 2008; Miller and
Raison, 2016; Pariante, 2017). For example, elevated levels of inter-
leukin (IL) IL-1β, IL-6, tumor necrosis factor alpha (TNFα) and C-re-
active protein (CRP) (Scrandis et al., 2008; Christian et al., 2009;
Cassidy-Bushrow et al., 2012; Azar and Mercer, 2013; Haeri et al.,
2013), and of corticotrophin releasing hormone (CRH) and cortisol
(Rich-Edwards et al., 2008; O’Keane et al., 2011; O’Connor et al.,
2013b), have all been described in association with antenatal symptoms
of depression. However, no studies have examined both inﬂammation
and HPA axis in the same depressed pregnant women. Accordingly,
MDD is theoretically an ideal paradigm by which to study the molecular
mechanisms underlying developmental programming.
Of note also is that developmental programming studies so far have
only measured the associations between two variables at a time, lim-
iting our understanding of the connections of antenatal depression with
both oﬀspring behavior and stress-related biology. For example, studies
have found associations (i) between antenatal symptoms of depression
and oﬀspring HPA axis or inﬂammation (Field et al., 2004b; Brennan
et al., 2008; Davis et al., 2011a; Vedhara et al., 2012; O’Donnell et al.,
2013; Plant et al., 2016); or (ii) between antenatal HPA axis and oﬀ-
spring HPA axis (Gutteling et al., 2004, 2005; Davis et al., 2011b;
O’Connor et al., 2013a); or (iii) between antenatal HPA axis and infant
behaviors or cognitive and motor development (de Weerth et al., 2003;
Huizink et al., 2003; Davis et al., 2007; Davis and Sandman, 2010); or
(iv) between antenatal inﬂammation and behavioral outcomes in oﬀ-
spring (Graham et al., 2017). We are lacking a study combining a
prospective assessment of: (i) clinically signiﬁcant levels of antenatal
stress in the form of MDD; (ii) antenatal maternal inﬂammation and
HPA axis; (iii) gestational outcomes; (iv) oﬀspring neurobehavioral
function and development; and (v) oﬀspring HPA axis. The current
study, aptly called Psychiatry Research and Motherhood – Depression
(PRAM-D) Study, addresses this existing gap in the literature by
studying women with MDD in pregnancy (and healthy pregnant




In a prospective longitudinal observational study, we compared a
cases group with a DSM-IV diagnosis of MDD in pregnancy (and their
oﬀspring) with a control group of healthy pregnant women (and their
oﬀspring) up to one year postnatally. Maternal socio-demographics,
obstetric and physical risk factors, together with clinical status and
inﬂammatory markers, were assessed at baseline (25 weeks gestation),
and HPA axis at 32 weeks of pregnancy. Gestational age at birth and
birth weight were recorded, and neonatal neurobehavioral function was
assessed at 6-days postnatal. Infant cortisol reactivity (response to the
pain stress of routine immunizations) and basal activity (morning and
evening) was also assessed at 2- and 12-months postnatal. Finally, in-
fant development was assessed at 12-months postnatal. Outcome
measures were assessed blind to caseness. The study was approved by
King’s College Hospital Research Ethics Committee, and all participants
provided written informed consent.
2.2. Sample
The sample comprised 106 women recruited in the late second tri-
mester of pregnancy (25 weeks gestation): 49 cases with MDD in
pregnancy (referred to Maudsley Perinatal Psychiatry Services) and 57
healthy controls (attending routine antenatal ultrasound scan) all at
King’s College Hospital. Of the 49 cases, 31 (63%) met DSM-IV criteria
for MDD at 25 weeks gestation (baseline visit) and 18 (37%) were as-
sessed to have met criteria for MDD in early pregnancy but not any
longer by baseline. Of the total sample, 41 (84%) had a past history of
MDD. Inclusion criteria were: women over 18 years of age with a sin-
gleton pregnancy; cases with a DSM-IV diagnosis of MDD in pregnancy;
and controls without any current or past DSM-IV axis I diagnosis.
Exclusion criteria were: uterine anomaly, known obstetric complica-
tions in the index pregnancy, severe or relevant chronic medical con-
ditions, such as cardiovascular disease, metabolic or endocrine dis-
order, for example gestational diabetes and hypertension. Cases were
excluded if presenting with any current DSM-IV diagnosis other than
co-morbid anxiety disorder, if having a past history of psychosis or
bipolar aﬀective disorder, or if taking antidepressant medication at
baseline.
As expected in a longitudinal study of an inner city group of people,
subject retention reduced over time, and at 1 year postnatal only 87
mother-infant dyads (51 controls and 36 cases) were assessed.
However, there was no statistically signiﬁcant diﬀerence at any time
point between the proportion of cases and controls remaining in the
study; furthermore, there were no statistically signiﬁcant diﬀerences in
socio-demographic information at baseline between those who did and
did not complete the 1 year assessments, either for cases or for controls
(data not shown). However, subjects who did not complete the 1-year
assessment had higher BDI and STAI scores at baseline and a greater
proportion who had smoked in pregnancy (see below), which may have
inﬂuenced some of the ﬁndings (see Discussion).
2.3. Clinical assessment
All subjects were assessed for current and past DSM-IV axis I dis-
orders at baseline using the Structured Clinical Interview for DSM-IV
(SCID I – CV) (First, 1996). We additionally used (at baseline and 32
weeks gestation) the Beck Depression Inventory (BDI, version IA; (Beck
et al., 1961) and the State-Trait Anxiety Inventory (STAI; (Spielberger,
S. Osborne et al. Psychoneuroendocrinology xxx (xxxx) xxx–xxx
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1983), two self-rated instruments measuring intensity or frequency of,
respectively, depressive and anxiety symptoms. The BDI and STAI were
also administered at 6-days, 2- and 12-months postnatal.
The most relevant socio-demographic and medical factors are pre-
sented in Table 1. As expected, the group with MDD in pregnancy had
statistically signiﬁcant higher BDI and STAIS scores both at baseline
and 32 weeks gestation. No subjects were taking antidepressant medi-
cation at the baseline assessment, although 8 (16%) took anti-
depressants at some point during pregnancy (4 before and 4 after the
baseline visit). Perhaps not surprisingly when considering the known
risk factors for antenatal depression (Biaggi et al., 2016), depressed
women were more likely to be unmarried or not cohabiting with a
partner, to have achieved lower education, to have smoked in the index
pregnancy, to be unemployed or employed at a non-professional/
managerial level, or to be of black or another ethnic minority status
(Table 1). Pre-pregnancy body mass index (BMI) was numerically
higher in depressed women, but the diﬀerence was not statistically
signiﬁcant (Table 1). In order to condense the information from these
socio-demographic variables, the Index of Multiple Deprivation (IMD)
score was examined (Noble et al., 2004), a UK government measure of
relative deprivation for small areas that covers seven aspects of depri-
vation. Expectedly, IMD score was signiﬁcantly higher (more depriva-
tion) in cases compared with controls (Table 1). Moreover, IMD was
signiﬁcantly correlated with the socio-demographic variables and with
maternal ethnicity (range of r= .30–.42) but not with maternal
smoking in pregnancy; hence IMD and smoking in pregnancy were both
examined in analyses adjusting for potential confounders when ap-
propriate (see data analysis, below). The groups did not diﬀer in ob-
stetric history or obstetric risk factors at baseline, and there were no
signiﬁcant group diﬀerences in medical conditions, use of medication
other than antidepressant drugs, and other health indicators or health
behaviors (data not shown).
Compared with women who remained in the study, subjects who
did not complete the 1 year assessment had higher BDI (9.4 ± 10.6 v
16.1 ± 10.8, z= 2.5, p= 0.013) and STAI (35.8 ± 14.9 v
47.4 ± 13.4, z= 2.7, p= 0.006) scores at baseline and a greater
proportion who had smoked in pregnancy (11 (13%) v 8 (44%),
χ2(1) = 9.6, p= 0.005), which may have inﬂuenced some of the ﬁndings
(see Discussion).
2.4. Inﬂammatory markers
Blood was obtained between 12 pm and 3 pm at a visit early in the
third trimester (median=27.0 weeks, range 23.9–34.9 weeks); there
was no statistically signiﬁcant diﬀerence in gestational age at sample
acquisition between cases and controls (z= 1.1, p=0.28). All samples
were transported to the laboratory in a cooled box and processed within
2 h of venipuncture. Aliquots of serum were immediately frozen at
−80 °C pending analysis. Serum high sensitivity C-reactive protein
(hsCRP) was measured using an ELISA kit supplied by PZ Cormay,
Poland; the assay was analyzed in batches on the Cobas Mira (intra- and
inter-assay CV were 2.96% and 3.85% respectively). Serum IL-1α, IL-
1β, IL-2, IL-4, Il-6, IL-8, IL-10, TNFα, vascular endothelial growth factor
(VEGF), EGF, MCP-1, and INF-γ were measured using a cytokine chip
array kit supplied by Randox Laboratories, UK; the kit employs a
sandwich chemiluminescent immunoassay, described in our previous
work (Di Nicola et al., 2013). For IL-1α, IL-4 and INF-γ, > 50% of the
sample was at the lowest detectable level of the assay, so these mea-
sures were not included in the subsequent analyses.
2.5. Salivary cortisol
Maternal saliva samples were obtained in the third trimester
(median= 32.4 weeks, range 30.6–37.1 weeks); there was no statisti-
cally signiﬁcant diﬀerence in gestational age at sample acquisition
between cases and controls (z= 0.48, p=0.63). All subjects collected
two samples, using Salivettes containing a polymer swab (Sarstedt, UK),
at awakening and 8 pm. Cortisol awakening response (CAR) was as-
sessed in a subset (n=29) that also collected samples at +15min,
+30min, and +60min after awakening. Subjects were given a prac-
tical demonstration, verbal and written instructions, a recording log
and a mechanical timer for sample collection; emphasis was placed on
the accuracy of timings and procedure, and subjects were instructed not
to eat, drink or smoke in the ﬁrst hour after awakening or in the thirty
minutes before sample collection at 8 pm. There were no diﬀerences
between cases and controls, in awakening time (7:34 h ± 0:52), the
time of awakening sample collection (7:39 h ± 0:52), the interval be-
tween awakening and sample acquisition (6.70 min ± 11.35) and the
time of evening sample collection (20:09 h ± 0:39).
Infants’ saliva samples were collected by a researcher before and
20min after the routine immunizations at 2 and 12 months (median
age= 2.1 months, range 1.62–5.54, and =12.6 months, range
11.0–18.6, respectively); there was no statistically signiﬁcant diﬀerence
in age for infants of cases or controls at either time point (z= 1.3,
p=0.18, and z= 0.5, p= 0.62, respectively). Infants’ saliva samples
were also obtained on the following day, by the mother, at morning
awakening and at 8 pm. Care was taken to avoid feeding for 15min
before a sample was taken. A Salivette and Salimetrics childrens swab
(SCS) were used to collect saliva by the researcher on the immunization
day; while, for ease of use, a Sorbette arrow was used for infant saliva
collection the following day by the mother. As for mothers, a sample log
was used to record timings and relevant information. There were no
Table 1
Characteristics of the sample at baseline and 32 weeks gestation.
Control Case Statistical test and signiﬁcance
(n= 53–57) (n= 46–49)
Age (years), mean (SD) 32.2 (4.4) 30.7 (6.7) t(80.4) = 1.3, p= 0.20
Ethnicity, white, n (%) 43 (75.4) 24 (49.0) χ2(1)= 7.9, p=0.008
Education, A level or higher, n (%) 53 (93.0) 31 (63.3) χ2(1)= 14.1, p 0.001
Employment status, working outside the home, n (%) 46 (80.7) 26 (53.1) χ2(1)= 9.2, p=0.003
Classiﬁcation of employment, professional or managerial, n (%) 41 (71.9) 18 (36.7) χ2(1)= 13.2, p < 0.001
Marital status, married or cohabiting, n (%) 50 (87.7) 22 (44.9) χ2(1)= 22.2, p < 0.001
IMD score, mean (SD) 28.6 (8.0) 32.2 (10.2) t(87.5) =−2.2, p=0.031
Pre-pregnancy BMI, mean (SD) 23.1 (3.8) 24.6 (4.5) z=−1.73, p= 0.08
Cigarette use in index pregnancy, n (%) 2 (3.7) 17 (35.4) χ2(1)= 16.9, p < 0.001
Antidepressant before baseline, n (%) 0 4 (8.2) χ2(1)= 4.8, p=0.043
Antidepressant after baseline, n (%) 0 4 (8.2) χ2(1)= 4.8, p=0.043
BDI score at baseline, mean (SD) 3.8 (2.6) 19.3 (11.4) t(42.0) =−8.5, p=0.001
STAIS score at baseline, mean (SD) 27.4 (6.8) 50.8 (12.8) t(57.1)=-10.6, p=0.001
BDI score at 32 wks. gestation, mean (SD) 3.4 (2.6) 14.1 (10.3) t(31.7) =−5.4, p=0.001
STAIS score at 32 wks. gestation, mean (SD) 29.3 (8.3) 48.3 (14.0) t(47.5) =−6.3, p=0.001
Bold values signify statistical signiﬁcance.
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diﬀerences between infants of cases and controls, in awakening time
(7:27 h ± 1:05 at 2 months and 7:19 ± 1:01 at 12 months), the in-
terval between awakening and sample acquisition (15.6min ± 21.0 at
2 months and 14.7 ± 21.0 at 12 months) and the time of evening
sample collection (20:05 h ± 0:44 at 2 months and 19:43 ± 0:41 at
12 months).
Salivary samples were frozen at −20 °C pending analysis. Saliva
cortisol was measured using a high sensitivity salivary cortisol enzyme
immunoassay kit supplied by Salimetrics Europe Ltd, UK. Samples were
assayed in duplicate where an adequate volume of saliva allowed. The
inter-and intra-assay CV ranged from 8 to 11% and 6 to 10% respec-
tively. The formula for the area of a trapezoid (Pruessner et al., 2003)
was used to calculate (i) CAR area under the curve (AUCi) using the
four samples acquired within the ﬁrst hour of waking, and (ii) diurnal
cortisol secretion using awakening and evening cortisol values.
2.6. Neonatal neurobehavioral function and infant development
The Neonatal Behavioral Assessment Scale (NBAS) (Brazelton,
1995) was used to measure neurobehavioral function in term-born
babies at a median age of 6.0 days (range from 4 to 42 days); there was
no statistically signiﬁcant diﬀerence in age at NBAS between infants of
cases or controls (z=−1.0, p= 0.30). Twenty-eight behavioral items
were rated and pooled into ﬁve clusters (autonomic stability, motor,
orientation, range of state and regulation of state). The Bayley Scales of
Infant and Toddler Development (Bayley-III, BSID) were used to eval-
uate cognitive, language and motor development using a series of de-
velopmental play tasks (Bayley, 2005). BSID was used at a median age
of 13.1 months (range 12.0–15.4); there was no statistically signiﬁcant
diﬀerence in age at BSID between infants of cases or controls (z= 0.4,
p=0.65).
2.7. Data analysis
The statistical analyses were performed in SPSS Statistics Version 21
(IBM Ltd, UK). The analysis plan comprised cross-sectional group
comparisons of maternal antenatal biomarkers, birth outcomes, neo-
natal neurobehavior, infant HPA axis, and development in 1-year-olds,
as well as the associations between infant factors and maternal bio-
markers. For all statistical tests, the data were ﬁrst examined to ensure
that the assumptions of the General Linear Model (GLM) were met. In
order to reduce bias, data were winsorized or log-transformed prior to
analyses or the bootstrap method (with 1000 samples) was employed;
raw data are presented in the ﬁgures and tables. Pearson’s chi-square
(χ2) test of the independence of variables was used for the analysis of
categorical data. Pearson’s correlation (rp) was used for the analysis of
association between parametric continuous variables, and Spearman’s
correlation (rs) was applied to non-parametric continuous variables. In
univariate analyses, group comparisons of continuous data were made
using the independent samples t-test. For non-parametric data, the
Mann-Whitney test was used and the z score reported. Univariate
analyses that showed signiﬁcant diﬀerences between patients and
controls were repeated after adjustment for the IMD and smoking in
pregnancy if appropriate. Cohen’s δ was calculated to estimate the ef-
fect size for group diﬀerences, or eﬀect size was expressed by partial eta
squared (ηp2) where ANOVA and ANCOVA were applied. Family-wise
adjustment for multiple comparisons was used to identify the strongest
ﬁndings. Mean and standard error of the mean are presented in graphs.
3. Results
3.1. Women with antenatal depression have increased inﬂammatory
markers in the early 3rd trimester
Inﬂammatory markers (see Table 2) were compared between
women with and without MDD in pregnancy at a single time point in
the early 3rd trimester. Compared with controls, cases had statistically
signiﬁcantly higher IL-6 (δ=0.53), IL-10 (δ=0.53), TNFα (δ=0.90)
and VEGF (δ=0.56) (Table 2). These diﬀerences remained signiﬁcant
after adjusting for IMD (p values ranging< 0.001–0.041).
Potential confounders did not aﬀect these results. Smoking was not
associated with any of the inﬂammatory markers. Moreover, even
though pre-pregnancy BMI was not statistically diﬀerent between cases
and controls, we explored its possible association with inﬂammatory
biomarkers: BMI was negatively associated with IL-10 only; inclusion of
BMI in the covariate model for IL-10 did not change the ﬁndings. It is
important to highlight that only TNFα remained statistically signiﬁcant
after adjustment for multiple comparisons, and thus should be con-
sidered the most robust ﬁnding among the inﬂammatory biomarkers.
There was no statistically signiﬁcant diﬀerence between cases and
controls in IL-1β, IL-2, IL-8, EGF, MCP-1 or hsCRP (Table 2).
Finally, as documented in section 2.2, of the 49 cases who had been
depressed in pregnancy up to the baseline assessment, 31 (63%) cases
met DSM-IV criteria for MDD at the time of sample collection and 18
(37%) cases no longer met criteria; however, t-tests revealed no sta-
tistically signiﬁcant diﬀerence in the inﬂammatory markers between
cases who did and did not meet criteria for MDD at sample acquisition
(p values ranging 0.11–0.47), other than for IL-10, which was higher in
cases who did not meet criteria for depression at baseline than cases
who did (0.83 ng/l ± 0.39 vs. 0.57 ng/l ± 0.29 respectively,
t(39) =−2.45, p=0.019). These secondary analyses conﬁrm the no-
tion that depressed pregnant women maintain a pro-inﬂammatory
signature at the end of the second trimester even if their depression has
improved by then.
3.2. Women with antenatal depression have increased diurnal cortisol
secretion, and blunted cortisol awakening response, in the 3rd trimester
Basal HPA axis activity was compared between women with and
without MDD in the 3rd trimester. Depressed women had a higher
diurnal cortisol secretion (AUC, nmol/ml/minute; t(42.8)=−2.9,
p=0.006, δ=0.89; p= 0.001 after adjustment for IMD) (Fig. 1, Panel
A). Moreover, in terms of individual time-points, depressed women had
higher awakening cortisol levels (t(44.1) =−1.8, p= 0.07, δ=0.54;
p=0. 027 after adjustment for IMD), and signiﬁcantly higher evening
cortisol levels (t(81) =−2.9, p= 0.004, δ=0.64; p=0.006 after ad-
justment for IMD). Lastly, depressed women had a statistically sig-
niﬁcant smaller (blunted) CAR (AUCi, nmol/ml/minute; (t(47) = 2.4,
p= 0.020, δ=0.70; p=0.016 after adjustment for IMD) (Fig. 1, Panel
B).
Potential confounders did not aﬀect these results. Smoking was not
associated with these cortisol measures. Again, although pre-pregnancy
BMI was not statistically diﬀerent between cases and controls, we ex-
plored its possible association with the HPA axis measures; it was ne-
gatively associated with CAR only; inclusion of BMI in the covariate
model for CAR did not change the ﬁndings. Diurnal and evening cortisol
remained statistically signiﬁcant even after adjusting for multiple
comparisons. Finally, t-tests revealed no statistically signiﬁcant diﬀer-
ence in the HPA axis measures between cases who did and did not meet
criteria for MDD at the baseline visit (p values ranging 0.25-0.95).
3.3. Women with antenatal depression have babies with lower gestational
age at birth
Gestational age at birth for women with spontaneous onset of labor
was lower in babies of cases compared with those of controls, by ap-
proximately 8 days (mean weeks 39.2 ± 2.6 v 40.4 ± 1.4, t(69) = 2.9,
p= 0.005, δ=0.70; p=0.012 after adjustment for IMD), and smoking
was not associated with this measure. There was no statistically sig-
niﬁcant diﬀerence between cases and controls in any other obstetric
outcome or obstetric detail (Supplementary Material: Table S1).
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3.4. Neonates who had been exposed to antenatal depression have
suboptimal neurobehavioral function at 6 days postnatal
The neurobehavioral assessment (NBAS) of full-term babies con-
ducted at 6 days postnatal showed that babies exposed to antenatal
depression demonstrated poorer performance on all ﬁve clusters: au-
tonomic stability (δ=0.85), regulation of state (δ=0.61), range of
state (δ=0.53), orientation (δ=1.22) and motor (δ=0.45) (Table 3).
The analyses were adjusted for IMD and other potential confounders
(sociodemographic, health indicators, pregnancy, delivery or neonatal)
that diﬀered between cases and controls, including gestational age at
birth and smoking in pregnancy. For all the NBAS clusters, except
‘range of state,’ the eﬀect of depression remained signiﬁcant after ad-
justment for IMD and these other potential confounders (p values
ranging 0.001-0.036). For ‘range of state’ there was a signiﬁcant eﬀect
of smoking in pregnancy (p=0.030) and the eﬀect of depression was
no longer signiﬁcant after adjusting for this variable. Autonomic
stability, regulation of state and orientation remained statistically sig-
niﬁcant even after adjusting for multiple comparisons.
3.5. Infants who had been exposed to antenatal depression have normal
cortisol function at 2 months of age
Cortisol function of the two-month-old infants was assessed by
measuring cortisol before and 20min after immunizations, as well as
morning and evening levels.
For cortisol reactivity to stress (Fig. 2, Panel A), the mixed design
ANOVA revealed a statistically signiﬁcant within-subjects eﬀect of time
on cortisol (F(1, 81) = 27.0, p < 0.001, ηp2= .25), that is, cortisol in-
creased following immunization in both depression-exposed and non-
exposed infants. However, there was no interaction between caseness
and time (F(1,81)= 0.4, p=0.51, ηp2= .01) and no between-subjects
eﬀects (F(1, 81)= 0.6, p= 0.45, ηp2= .01). Thus, the magnitude of the
cortisol response did not diﬀer between those infants who had and had
not been exposed to antenatal depression.
Basal HPA axis activity in the eight-week-old infants was assessed
the day after their immunization by measuring awakening and evening
cortisol (mean time 07:47 h ± 1:08 and 20:05 h ± 0:45` respectively;
there was no diﬀerence in the time of sample acquisition between cases
and controls). There was no statistically signiﬁcant diﬀerence in either
measure between the exposed and non-exposed infants (p values 0.70
and 0.46 respectively) (Fig. 2, Panel B).
3.6. Infants who had been exposed to antenatal depression have hyperactive
cortisol responses at 12 months of age
Cortisol function of the 12-month-old infants was assessed, as at 2
months, by measuring cortisol before and 20min after the immuniza-
tions, as well as morning and evening levels.
For cortisol reactivity to stress (Fig. 2, Panel C), mixed design
ANOVA demonstrated a statistically signiﬁcant between-subjects eﬀect
Table 2
Antenatal depression and inﬂammatory markers in the early 3rd trimester.
Controls (n= 53–54) mean (SD) Cases (n=40–41) mean (SD) Statistical test and signiﬁcance
IL-1β (ng/l) 1.33 (1.16) 2.04 (4.94) t(91)=−0.4, p= 0.67
IL-2 (ng/l) 1.97 (2.11) 1.94 (2.15) t(92)= 0.3, p= 0.75
IL-6 (ng/l) 0.82 (0.60) 1.64 (3.12) t(68.9) =−2.2, p=0.031
IL-8 (ng/l) 2.02 (1.26) 4.95 (11.63) t(92)=−1.4, p= 0.18
IL-10 (ng/l) 0.66 (0.62) 1.55 (5.17) t(63.0) =−2.1, p=0.043
TNFα (ng/l) 1.10 (0.88) 1.59 (0.99) t(60.1) =−3.5, p=0.003
VEGF (ng/l) 3.20 (3.46) 6.47 (12.58) t(92)=−2.7, p=0.008
EGF (ng/l) 16.07 (23.85) 21.12 (26.82) t(58.9)=−1.8, p= 0.70
MCP-1 (ng/l) 51.56 (38.21) 67.66 (60.29) t(67.3)=−0.8, p= 0.40
hsCRP (mg/l) 5.31 (6.83) 5.14 (6.41) t(93)= 0.8, p= 0.43
Bold values signify statistical signiﬁcance.
Fig. 1. Antenatal depression and maternal hypothalamic-pituitary axis at 32
weeks gestation.
Table 3
Antenatal depression and neonatal neurobehavioral examination (NBAS).
Infants of
controls








6.17 (1.13) 5.26 (0.99) t(97)= 4.2, p < 0.001
Regulation of
state
6.39 (1.28) 5.52 (1.63) t(97)= 3.0, p=0.004
Range of state 3.30 (0.81) 3.66 (0.80) t(97)=−2.6, p=0.013
Orientation 7.49 (1.26) 6.47 (1.45) t(63.9)= 4.9, p=0.001
Motor 5.66 (0.70) 5.33 (0.81) t(97)= 2.1, p=0.049
Bold values signify statistical signiﬁcance.
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of caseness on cortisol levels (F(1, 72) = 0.5, p= 0.002, ηp2= .13), as
well as a statistical trend for an interaction between caseness and time
(F(1, 72)= 3.4, p= 0.07, ηp2= 0.05), but no within-subjects eﬀect (F(1,
72) = 1.9, p= 0.17, ηp2= 0.03). These statistical ﬁndings were driven
by an increase in cortisol levels following stress in the infants exposed
to antenatal depression, but not in the non-exposed infants (Fig. 2,
Panel C). In fact, infants exposed to antenatal depression had higher
cortisol levels after the immunization compared with control infants
(t(72) =−3.7, p < 0.001, δ=0.87) but not before (t(72) =−1.6,
p= 0.11, δ=0.38). The mixed design ANOVA used to measure the
cortisol response to stress takes account of the multiple testing, and thus
this group diﬀerence is statistically robust.
Given the well-established continuity between maternal antenatal
and postnatal depressive symptoms (Plant et al., 2017), in addition to
the potential confounders of IMD, smoking in pregnancy and gesta-
tional age at birth, we also examined the eﬀect of maternal postnatal
depressive symptoms (BDI) on these ﬁndings. We included maternal
depressive symptoms at 12 months (at the same time as the cortisol
assessment) as well as the total postnatal burden of maternal depressive
symptoms (the average BDI score at 6 days and at 2 and 12 months). As
expected, compared with control women, women with antenatal de-
pression had higher BDI score both at 12 months postnatal (9.7 ± 9.2
vs. 3.3 ± 3.4, t(29.4) =−3.4, p= 0.002, δ=1.25) and as total post-
natal burden (9.9 ± 7.6 vs. 3.5 ± 2. 9, t(33.2) =−4.6, p < 0.001,
δ=1.60). Only average postnatal symptoms of depression were asso-
ciated with the infant cortisol, therefore average postnatal BDI and IMD
were included in the ANOVAS. The between-subjects eﬀect of caseness
in the mixed design ANOVA remained signiﬁcant (p=0.024), as did
the diﬀerence between exposed and non-exposed infants in the post-
immunization cortisol (p= 0.021). Thus, the increase in cortisol levels
following stress in the infants exposed to antenatal depression was not
driven by the postnatal depressive symptoms or other potential con-
founding factors.
Lastly, as at 2 months, basal cortisol activity in the 12-month-old
infants was assessed the day after their immunization by measuring
awakening and evening cortisol levels (mean time 07:37 h ± 0:57, and
19:42 h ± 0:40, respectively; there was no diﬀerence in the times of
sample acquisition between cases and controls). Infants exposed to
antenatal depression had higher evening cortisol at 12 months
(t(62) =−2.4, p= 0.020, δ=0.61), but not morning cortisol,
(t(62) =−0.7, p= 0.49, δ=0.18 (Fig. 2, Panel D). As for cortisol
stress-response, we examined the eﬀect of IMD, smoking in pregnancy,
gestational age at birth and concurrent and total postnatal burden of
maternal postnatal depressive symptoms. Again, only average postnatal
symptoms of depression were associated with infant cortisol, therefore
average postnatal BDI and IMD were included in the ANOVAS. The
diﬀerence in evening cortisol became non-signiﬁcant after adjustment
for IMD and average postnatal BDI (p=0.44). Therefore, the higher
evening cortisol levels in infants exposed to antenatal depression were
driven by the socio-demographic factors and by maternal postnatal
depressive symptoms.
3.7. Infants who had been exposed to antenatal depression have normal
development at 12 months postnatal
Compared with infants of healthy women (n= 50), those exposed
to depression in utero (n=35) did not diﬀer in cognitive
(114.3 ± 14.0 vs. 109.6 ± 14.0, t(83) = 1.5, p= 0.11), language
(100.9 ± 12.4 vs. 98.6 ± 12.3, t(83) = 1.4, p= 0.16) or motor
(101.4 ± 10.4 vs. 103.6 ± 12.0, t(83) =−0.9, p= 0.38) development
at 12 months of age, as measured by BSID. The ﬁndings are the same
both for the entire sample and solely for full-term infants.
3.8. Associations between maternal antenatal stress-related biology and
infant measures
Correlations were used to examine the associations between ma-
ternal antenatal measures that diﬀered between cases and controls (i.e.,
inﬂammatory markers and cortisol levels) and the infant measures that
diﬀered between cases and controls and were uniquely explained by the
antenatal exposure (i.e., gestational age at birth, NBAS, and post-stress
cortisol at 12 months) (Table 4).
There were no correlations between maternal antenatal biomarkers
and gestational age at birth. However, there were statistically sig-
niﬁcant correlations between maternal biomarkers (TNFα, VEGF, IL-10
and diurnal cortisol) and the NBAS scores of full-term babies (auto-
nomic stability, regulation of state, and orientation; range of all
r= 0.22–0.28, all p values< 0.05). These correlations were all in the
Fig. 2. Infant cortisol at 2 and 12 months.
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expected direction, i.e., elevated biomarker levels correlated with less
optimal neurobehavioral function. There were also statistically sig-
niﬁcant correlations between maternal biomarkers (TNFα, VEGF, IL-10
and evening cortisol) and infant cortisol after the immunizations at 12
months (all r ranging from 0.28 to 0.47, all p values< 0.022). Again,
these correlations were all in the expected directions, i.e., elevated
maternal antenatal biomarker levels correlated with higher infant cor-
tisol. Taken all together, these correlations support the notion that
neonatal neurobehavioral function at 6 days and cortisol stress response
at 12 months are an embedded biological programming eﬀect that is
associated with the antenatal biological changes found in women with
MDD in pregnancy.
4. Discussion
We used a prospective longitudinal design and demonstrated that
women with clinically-signiﬁcant antenatal MDD have: (i) abnormal
stress-related biology (inﬂammation and cortisol) in pregnancy; (ii)
shorter length of gestation; (iii) neonates with sub-optimal neurobe-
havioral function; and (iv) one-year-old infants with increased cortisol
reactivity to stress. Our ﬁndings are in keeping with the hypothesis that
maternal antenatal MDD has a programming eﬀect on oﬀspring neu-
robehavioral function and HPA axis activity, and, furthermore, that
maternal antenatal inﬂammation and cortisol are involved in the me-
chanistic pathway of these programming eﬀects.
4.1. Maternal antenatal stress-related biology
Compared with healthy women, those with antenatal MDD have
higher levels of 3rd trimester inﬂammatory markers (IL-6, IL-10, VEGF
and TNFα), HPA axis overactivity as indexed by raised evening cortisol
and increased total daily cortisol secretion, and a blunted cortisol
awakening response. Our ﬁndings are broadly consistent with previous
literature, although the ﬁndings from previous studies of antenatal
depression and inﬂammation or HPA axis appear mixed, and they are
diﬃcult to compare as they use diﬀerent deﬁnitions or measures of
depression and diﬀerent measurements of inﬂammation or HPA axis, at
diﬀerent stages of gestation, diﬀerent times of day and in diﬀerent
tissues. The most-studied inﬂammatory markers are CRP, IL-1b, IL-6
and TNFα, which are all more commonly raised in relation to increased
depressive symptomatology (Scrandis et al., 2008; Christian et al.,
2009; Cassidy-Bushrow et al., 2012; Azar and Mercer, 2013; Haeri
et al., 2013), than lowered (Shelton et al., 2015; Edvinsson et al., 2017);
however, these same studies also have null ﬁndings for some of these
inﬂammatory markers.
The majority of studies of the HPA axis and operationally deﬁned
depression have demonstrated higher saliva cortisol (Evans et al., 2008;
Monk et al., 2011; O’Keane et al., 2011), and studies comparing
pregnant women with high or low levels of self-rated symptoms of
depression largely (Lundy et al., 1999; Field et al., 2001, 2004b;
Parcells, 2010; Peer et al., 2013), but not always (Shea et al., 2007;
Braithwaite et al., 2016), report increased cortisol. In general, for the
HPA axis the ﬁndings appear to be more robust when depression is
present at disease level. In contrast with our ﬁndings, two studies using
diagnostic interviews have shown no eﬀect of antenatal depression on
CAR (Hellgren et al., 2013; O’Connor et al., 2013b). However, both
studies were broader in their inclusion of not only major depression,
but also minor depression and/or depression ‘not otherwise speciﬁed’
(NOS) or deﬁned as high scores on EPDS. Furthermore, although
O’Connor et al. (2013b) measured CAR at a similar length of gestation
as our study, Hellgren et al. (2013) measured CAR relatively late in
pregnancy, at 36–39 weeks gestation; thus, overall these studies are not
directly comparable to ours. Animal studies of prenatal stress (PNS)
mirror our ﬁndings: for example, corticosterone is elevated in pregnant
rats subjected to electric tail shock or restraint stress (Ward and Weisz,
1984; Weinstock et al., 1988; Takahashi et al., 1998; Williams et al.,
1999) and in pregnant rhesus monkeys subjected to noise stress
(Schneider et al., 1999).
Maternal antenatal HPA axis is critical in pregnancy physiology,
e.g., fetal maturation and timing of parturition. Consistent with this,
and with previous research, depressed women in our study do indeed
have shorter length of gestation. Previous meta-analyses have also
shown an association between antenatal depression and preterm birth
(Grote et al., 2010; Grigoriadis et al., 2013), although the evidence for
shortened length of gestation per se is mixed (Van Dijk et al., 2010;
O’Keane et al., 2011; Grigoriadis et al., 2013). Interestingly, we ﬁnd no
signiﬁcant correlations between maternal inﬂammatory biomarkers
and shorter length of gestation, while two previous studies did: Blair
et al. (2015) found a negative correlation between IL-8 (at 19–30 weeks
gestation) and length of gestation, although this ﬁnding was only ap-
parent in African American (n= 79), not European American women;
and Coussons-Read et al. (2012) found a negative correlation between
both IL-6 and TNFα (at 28–30 weeks gestation) and length of gestation
in 173 mostly Hispanic women, who were free from psychiatric dis-
order. We found a statistical trend for a negative correlation between
IL-6 and gestational age, while the other correlations were in the same
direction but not statistically signiﬁcant (Table 4). The clearer ﬁndings
in these two aforementioned papers might be explained by the diﬀerent
ethnicity of the populations under study as well as possibly (for
Coussons-Read et al., 2012) by a larger statistical power. Regarding
previous studies of maternal HPA axis activity and length of gestation,
the most robust ﬁnding is the relationship between preterm birth and
raised CRH (which was not examined in this study) (McLean et al.,
1995; Wadhwa et al., 1998; Sandman et al., 2006).
Table 4
Correlations for maternal antenatal and infant measures.




NBAS Orientation NBAS Motor 1 year-old infant’s cortisol after the
immunizations
Diurnal cortisol 0.05 −0.14 0.03 −0.08 −0.01 0.28*
Evening cortisol −0.14 −0.02 −0.1 −0.12 0.11 0.32**
CAR (AUCi) 0.17 0.04 −0.11 0.1 0.04 −0.29
IL-6 −0.21 −0.02 −0.18 −0.08 0.15 0.15
IL-10 −0.14 −0.07 −0.28** −0.05 0.04 0.35*
TNFα −0.12 −0.22* −0.11 −0.18 −0.06 0.37**
VEGF −0.08 −0.23* −0.09 −0.22* 0 0.47***
Note. Correlation coeﬃcient - Spearman’s r.
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4.2. Infant cortisol stress reactivity
The principal focus of this study was to examine the developmental
programming eﬀects of in utero exposure to MDD on oﬀspring cortisol
reactivity to the stress of immunization. We found that, compared with
infants of healthy women, those exposed to MDD in utero show a larger
cortisol stress response at 12, but not at 2 months. This increased post-
stress cortisol persists when symptoms of postnatal maternal depression
are taken into account, indicating a biologically embedded antenatal
eﬀect. To our knowledge, this is the ﬁrst prospective study linking
operationally deﬁned antenatal MDD and cortisol response to stress in
1-year-old oﬀspring, and our ﬁndings extend and conﬁrm previous
studies of PNS and infant stress response both in humans and in animals
(Weinstock, 2008). For example, high levels of antenatal symptoms of
depression in a non-clinical sample were associated with a larger cor-
tisol response to immunization in infants (Fernandes et al., 2015). Si-
milarly, higher levels of maternal daily hassles and pregnancy-related
anxiety were associated with higher cortisol in the 30min after im-
munization in four- to six-year-old children (Gutteling et al., 2004).
However, antenatal perceived stress predicted greater cortisol reactivity
to heelstick in neonates in one study (Leung et al., 2010) but not an-
other (Davis et al., 2011a): these contrasting ﬁndings may be explained
by retrospectively-rated stress in the ﬁrst but not the second study. In
animals, we and others have shown that adult rats born from dams
exposed to restraint stress in the last week of gestation show HPA axis
hyperactivity, depressive-like behavior, and changes in hippocampal
gene expression that are overlapping to those found in the blood of
depressed patients (Anacker et al., 2013a, b; Cattaneo et al., 2018).
Interestingly, previous research has shown that a cortisol stress re-
sponse is apparent at birth, but that it diminishes with age, such that by
12 months there is little or no cortisol response to pain (Jansen et al.,
2010). This is the ﬁrst study to show that, in contrast to the typically
expected lack of cortisol response to pain stress in 12-month-olds, the
response persists in those infants who had been exposed to MDD in
utero. In contrast, at 2 months there was a comparable increase in
cortisol in both cases and controls. This demonstrates that the eﬀect of
antenatal MDD in utero is not apparent at an early postnatal stage but it
does become apparent later, at a developmental stage when healthy
infants generally no longer exhibit a cortisol stress response.
4.3. Associations between maternal stress-related biology and infant cortisol
In our study, infant cortisol after the immunization at 12 months is
signiﬁcantly, positively correlated with maternal antenatal in-
ﬂammatory markers (IL-10, TNFα and VEGF) and evening cortisol.
These correlations are in the same direction as hypothesized, i.e.
women with antenatal MDD have higher IL-10, TNFα, VEGF and eve-
ning cortisol in pregnancy, and their infants have higher cortisol after
their immunizations. This association supports the hypothesis of a
mechanistic link between the antenatal biological environment and
oﬀspring cortisol stress regulation. Moreover, these ﬁndings extend
those of other studies in humans that demonstrate an association be-
tween maternal antenatal cortisol (Gutteling et al., 2004, 2005; Davis
et al., 2011a), or amniotic ﬂuid cortisol (O’Connor et al., 2013a), and
infant cortisol stress response. Further supporting these ﬁndings, re-
search in rodents has shown that an immune challenge during preg-
nancy augments the oﬀspring HPA axis stress-response (Reul et al.,
1994; Samuelsson et al., 2004). Moreover, animal studies using adre-
nalectomized pregnant rodents have provided a deﬁnitive demonstra-
tion that maternal glucocorticoids mediate the long-term eﬀects of
prenatal stress on oﬀspring HPA axis activity (Barbazanges et al., 1996;
Maccari et al., 2003; Wilcoxon and Redei, 2007). Interestingly, the
notion that antenatal depression speciﬁcally programs cortisol stress
reactivity through maternal inﬂammation and cortisol functions is
further supported by our ﬁnding that the evening cortisol of 12-month
infants, a measure of resting HPA axis, is linked to postnatal maternal
depression.
4.4. Oﬀspring neurobehavioral function and development
Compared with neonates of healthy women, those exposed to MDD
in utero show suboptimal neurobehavioral function at 6 days, indexed
by NBAS examination; however, there is no group diﬀerence in cogni-
tive, language or motor development at 12-months of age. The ﬁndings
in neonates mirror previous studies of antenatal depression and oﬀ-
spring neurobehavioral function, as described in the introduction (Field
et al., 2004a; Diego et al., 2005; Goodman et al., 2011; Pacheco and
Figueiredo, 2012), and further demonstrate that the adverse eﬀect of
MDD in pregnancy is not limited to pregnancy biology and its im-
mediate sequelae, but extends to aﬀect the oﬀspring. Of note, only one
NBAS cluster, ‘range of state’, seems to be inﬂuenced more by maternal
smoking and mode of delivery than by antenatal depression per se.
‘Range of State’ measures infant arousal, lability and irritability; and
previous studies of NBAS and smoking in pregnancy are in keeping with
the ﬁnding of an eﬀect of smoking on irritability, although these studies
did not control for maternal mood (Oyemade et al., 1994; Mansi et al.,
2007; Hernandez-Martinez et al., 2012). Likewise, the above-mentioned
studies of antenatal depression and NBAS did not control for maternal
smoking. Our study is the ﬁrst to demonstrate that some neurobeha-
vioral abnormalities in infants exposed to antenatal depression are di-
rectly related to the in utero biology (see below) while others appear to
be related to smoking in pregnancy.
As mentioned above, some NBAS clusters are signiﬁcantly corre-
lated with maternal antenatal inﬂammatory and HPA axis markers.
These correlations are in the same direction as hypothesized, i.e., ele-
vated maternal antenatal stress-related markers are associated with less
optimal NBAS scores, again supporting the hypothesis of a mechanistic
link for these neurobehavioral outcomes. Other studies have demon-
strated associations between maternal antenatal inﬂammation and
oﬀspring behavior; for example, a study has shown that IL-6 is asso-
ciated with impulse control in 2-year-old oﬀspring (Graham et al.,
2017). Moreover, maternal antenatal HPA axis has also been previously
associated with oﬀspring behaviors, such as crying and fussing in babies
from one to seven weeks of age (de Weerth et al., 2003) or negative
reactivity at 2 months (Davis et al., 2005, 2007). However, these stu-
dies have not examined this association within the context of clinically
signiﬁcant depression. Animal evidence also supports our ﬁnding; for
example, maternal antenatal immune activation in mice has long-term
eﬀects on oﬀspring behavior, such as deﬁcient social and commu-
nicative behavior (Malkova et al., 2012), and on brain structure and
histopathology, such as altered pyramidal and nonpyramidal cell den-
sity (Fatemi et al., 2002); and oﬀspring of rats given synthetic gluco-
corticoids in pregnancy display increased depressive and anxious be-
havior (Oliveira et al., 2006).
The lack of eﬀect of antenatal depression on developmental out-
comes at 12 months is potentially surprising. However, there are lim-
ited data in humans on the eﬀects of depression in pregnancy on oﬀ-
spring developmental outcome, and results are conﬂicting (Waters
et al., 2014). Some large studies of oﬀspring of women with a high level
of symptoms of depression in pregnancy (> 1000 of children, ranging
from 18-months to 8-year-olds) have found developmental delay, de-
creased cognitive development, and lower IQ (Deave et al., 2008; Tse
et al., 2010; Evans et al., 2012). Likewise, a study of> 200 18-month-
old children found an association between high levels of symptoms of
depression and lower cognitive development (Koutra et al., 2013).
However, another study of> 300 children using the same scale as our
study and administered at the same time-point (the BSID at 12 months)
found no such relationship (Bandoli et al., 2016). In the current study
we found that both cognitive and language scores were numerically
lower in infants of depressed mothers, although the diﬀerences did not
reach statistical signiﬁcance. Thus, the lack of ﬁnding may have been
an issue of power, or alternatively due to the developmental stage of the
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children. Clariﬁcation of the eﬀect of antenatal depression on infant
development requires further follow-up study in these children. As
discussed below, it is possible that the lack of diﬀerence in the BSID
scores may be partly due to the analyses being limited to a less severely
depressed sample.
4.5. Limitations
Despite a number of important strengths, including the prospective
design, diagnostic assessment by semi-structured interview, and a
broad assessment of inﬂammation and HPA axis markers in women and
oﬀspring over time, there are some limitations. First, subjects were
drawn from a population with broad diversity in socio-economic status
and ethnicity; although we have controlled for social deprivation
(IMD), the numbers were too small to complete any analyses in speciﬁc
social or ethnic subgroups. Furthermore, subjects were medically
healthier compared with a general pregnant population, due to the
exclusion criteria for the study, and indeed their pre-pregnancy BMI
was not associated with depression. Second, the majority of cases had a
previous history of depression or of other (non-psychotic) mental dis-
orders, and we cannot exclude a genetic component linking maternal
psychopathology with oﬀspring biological or behavioral changes;
nevertheless, we have been able to show that our main ﬁnding – the
increase oﬀspring cortisol response - is driven by depression in preg-
nancy and not by depression in the postpartum, thus indicating that
speciﬁc eﬀects are present for depression in pregnancy, over and above
any generic risk associated with depression at other times. Third, al-
though cases were free from antidepressant medication at baseline, 8
subjects took antidepressants later in pregnancy. These eﬀects could not
be quantiﬁed because of the infrequency of this potential confounding
factor; however, exclusion of these eights subjects from the analyses did
not change the ﬁndings (data not shown). Forth, principally because of
diﬃculties recruiting such an unwell group of pregnant women, the
sample size is relatively small. This limitation is compounded by sample
attrition over the 15 months of study, and those who dropped out had
higher BDI and STAI scores at baseline; thus, perhaps understandably,
those who had more severe psychopathology early in pregnancy then
seem to have struggled to remain involved in the study. Overall, these
ﬁndings do not detract from our main biological ﬁnding in infants (the
increased cortisol response at 12 months), as these new data show that
this eﬀect is present also in the potentially less severe group of women
and their infants who had the follow-up visit. However, as mentioned
above, it is possible that the lack of diﬀerence in the BSID scores may be
partly due to the analyses being limited in this less severe sample. Fifth,
undoubtedly, the study’s impact comes from the coexisting measures of
both biological and clinical variables from both mothers and infants,
over pregnancy and the ﬁrst postnatal year. However, this brings the
potential confounder of multiple comparisons. We have therefore con-
ducted family-wise adjustment, and identiﬁed that the diﬀerences in
maternal TNFα and diurnal and evening cortisol levels, and in infants’
autonomic stability, regulation of state, orientation as well as cortisol
response to stress at 12 months, as the most statistically robust ﬁndings.
Lastly, it is essential to emphasize that the proposed causative biolo-
gical pathways, linking maternal cortisol and inﬂammatory biomarkers
with infants’ NBAS scores and cortisol response to stress, are only
supported by correlational analyses. Although these correlations are all
in the expected direction, i.e., elevated maternal biomarker levels
correlating with less optimal neurobehavioral function and higher
cortisol response in infants, only testing for mediation would be able to
unequivocally conﬁrm these causal pathways. This, however, is inad-
visable in our study due to the limited sample size. As such, these as-
sociations should considered at best suggestive, and requiring further
validation and replication in larger samples.
In conclusion the current study has addressed an existing gap in
the literature regarding the possible programming eﬀects of oper-
ationally deﬁned, clinically signiﬁcant antenatal depression, and
represents the ﬁrst step towards understanding the convergent in-
ﬂammation- and cortisol-related mechanisms for developmental pro-
gramming in humans. Studying the eﬀects of depression at a disease
level ensures that stress is meaningful and produces clinically sig-
niﬁcant impairment. Most importantly, antenatal depression is common
(Gavin et al., 2005) and is associated with adverse obstetric outcomes
(Grote et al., 2010; Grigoriadis et al., 2013), but is also readily diag-
nosed and treated, thus providing an opportunity for intervention
(Pariante, 2015), ultimately preventing the transmission of abnormal
stress biology, and related psychopathology, to the next generation.
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